Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-12-02 pm EST
178.88 USD   +0.08%
12/03Johnson & Johnson : Announcement for the purposes of Rule 2.8 of the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the “Irish Takeover Rules”)
PU
12/02Insider Sell: Johnson & Johnson
MT
12/02Sanofi Says Any Potential Offer for Horizon Therapeutics Will Be Made in Cash
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson - Diversifying Our Health Workforce through the Impact of AIM

09/22/2022 | 11:58am EST

Johnson & Johnson and National Medical Fellowships (NMF) celebrate completing the inaugural cohort's first year of the innovative three-year service-learning program. In alignment with Our Race to Health Equity (ORTHE), the program exposes diverse medical students to medical professionals within pharmaceutical medicine and equips them with the skills and support needed to address health disparities.

In the fall of 2021, 20 high-performing underrepresented medical students from across the country were selected to participate in the inaugural cohort of the Alliance for Inclusion in Medicine (AIM) Scholarship program. In addition to scholarship funding, the program provides Black, Indigenous and People of Color (BIPOC) medical students with the unique opportunity to receive guidance and career insights from Johnson & Johnson physician mentors who provide support for the scholars as they navigate a career in medicine and aspire to address healthcare's structural and systemic barriers that disproportionately affect communities of color.

Addressing health inequities is a daunting challenge, but through the ORTHE commitment, Johnson & Johnson envisions creating a lasting impact through the change agents and future healthcare leaders of tomorrow. This meaningful collaboration and partnership between Johnson & Johnson and NMF has had tangible outcomes for the fellows who have dedicated their time and effort to become advocates for health equity through their work. These scholars and future cohorts of scholars will go on to treat countless patients. They will help improve the lives of patients through a lens of health equity, social justice, and racial justice. As they grow in their careers, they will be able to share their insights learned through their training and expertise from Johnson & Johnson physicians with colleagues in various healthcare settings.

Thus, the breadth and scope of the impact of AIM are boundless, and the first year of scholars' experience has been breathtaking!

Along with mentorship support, scholars participated in engaging learning sessions on topics including drug development, drug safety, statistics, real-world evidence, scientific publications, clinical trial protocols, epidemiology and more. These learning sessions taught scholars the essential skills to make lasting improvements to healthcare systems that best serve diverse patient populations. Scholars also shared how the program strengthened their commitment to pursue a medical career where prioritizing diversity and providing first-class care to historic and presently marginalized BIPOC patients is at the center of their work.

As they continue their journey to becoming the healthcare leaders of tomorrow, we look forward to seeing the incredible impact these exceptional scholars will have in their communities and the patients they serve. Stay tuned as we get ready to welcome the AIM program's second cohort of scholars in the coming months!

Look through these scholar reflection quote cards to find out how these exceptional medical students are working towards mitigating health inequities.

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about JOHNSON & JOHNSON
12/03Johnson & Johnson : Announcement for the purposes of Rule 2.8 of the Irish Takeover Panel ..
PU
12/02Insider Sell: Johnson & Johnson
MT
12/02Sanofi Says Any Potential Offer for Horizon Therapeutics Will Be Made in Cash
MT
12/01Global markets live: General Electric, Tesla, Apple, Salesforce, Boe..
MS
12/01There are two ways to look at Powell's speech
MS
12/01Morgan Stanley Adjusts Price Target on Johnson & Johnson to $178 From $170, Maintains E..
MT
12/01First Wave BioPharma Files IND For Enhanced Formulation Of Adrulipase; Topline Results ..
AQ
12/01Johnson & Johnson : Change in Directors or Principal Officers, Financial Statements and Ex..
AQ
11/30J&J CEO Joaquin Duato to take additional role of Chairman
RE
11/30Johnson & Johnson Chief Executive Joaquin Duato to Also Assume Chairman Role
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 035 M - -
Net income 2022 20 677 M - -
Net cash 2022 10 806 M - -
P/E ratio 2022 22,0x
Yield 2022 2,43%
Capitalization 468 B 468 B -
EV / Sales 2022 4,81x
EV / Sales 2023 4,59x
Nbr of Employees 141 700
Free-Float 83,8%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 178,88 $
Average target price 181,90 $
Spread / Average Target 1,69%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON4.57%467 679
ELI LILLY AND COMPANY35.67%356 089
ABBVIE INC.20.87%289 331
NOVO NORDISK A/S22.04%285 887
PFIZER, INC.-13.78%285 774
MERCK & CO., INC.43.58%278 995